ABBV-CLS-628
Asset
Investigational drug for autosomal dominant polycystic kidney disease
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Autosomal dominant polycystic kidney disease
Phase 2, calicolabs.com, 10 Oct 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.